Atlas Trials

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Clinical trial NCT02572167 · COMPLETED

Trial details

NCT number
NCT02572167
Sponsor
Seagen Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2015-10-31
Primary completion
2018-03-01
Enrollment
93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.